By Andrea Figueras Shares in Grifols jumped Monday after the company said the sale of its 20% interest in Chinese medicine developer Shanghai RAAS Blood.
(Bloomberg) Grifols SA shares slumped anew, putting the stock on a pace for its biggest weekly drop ever after a short seller criticized the Spanish blood-plasma company’s accounting and corporate governance.Most Read from BloombergGoogle Lays Off Hundreds in Hardware, Assistant, EngineeringUS and UK Strike Yemen’s Houthis After Red Sea Ship AttacksHertz to Sell 20,000 EVs in Shift Back to Gas-Powered CarsUK’s Sunak Authorizes Joint Military Strikes With US Against HouthisSEC Authorizes Bitco
Pharmaceutical company Grifols (GRFS) faced a significant setback following the release of a report by Gotham City Research. The report accused the firm of serious accounting manipulations, raising concerns about its stock value.
From uncertain SEC bitcoin ETF approval, global unemployment reaching 5.2 percent to Tesla s Model 3 redesign, Honda s EV plans, OpenAI s GPT Store debut, here s a look at some of the developments from the world of business